Ebner Stolz successfully advises on the sale of Nanoscribe to the listed CELLINK Group

• Na­no­scribe, the pioneer and mar­ket lea­der in high-pre­ci­sion ad­di­tive ma­nu­fac­tu­ring, strengt­hens its stra­te­gic po­si­tion by joi­ning the CEL­LINK Group
• With this stra­te­gic di­ver­si­fi­ca­tion, the CEL­LINK Group gains a bre­ak­th­rough tech­no­logy that is dri­ving in­no­va­tion in many areas, in­clu­ding me­di­cal tech­no­logy, bio­prin­ting and mi­cro/na­no­fa­bri­ca­tion
• Eb­ner Stolz ad­vi­sed with a mul­ti­di­sci­pli­nary team

Stutt­gart, 1 June 2021 - A mul­ti­di­sci­pli­nary team of ad­vi­sors from Eb­ner Stolz has suc­cess­fully ad­vi­sed the share­hol­ders of Na­no­scribe on the sale of their sha­res in CEL­LINK.

With over 80 em­ployees in Ger­many, China and the USA, Na­no­scribe de­ve­lops and sells 3D prin­ters and mas­kless li­tho­gra­phy sys­tems for mi­cro­fa­bri­ca­tion, as well as spe­cially de­ve­lo­ped pho­to­re­sists and ap­pli­ca­tion-spe­ci­fic com­plete so­lu­ti­ons. The spe­cia­list for the ad­di­tive ma­nu­fac­tu­ring of high-pre­ci­sion struc­tures and ob­jects on the nano, mi­cro and meso scale was foun­ded in 2007 as a spin-off of the Karls­ruhe In­sti­tute of Tech­no­logy (KIT). World­wide, more than 2,500 users and ope­ra­tors at top uni­ver­si­ties and in in­no­va­tive in­dus­trial com­pa­nies be­ne­fit from the ground­brea­king tech­no­logy and ap­pli­ca­tion-spe­ci­fic so­lu­ti­ons for 3D mi­cro­fa­bri­ca­tion. The strong, mar­ket-lea­ding po­si­tion is ba­sed on high-qua­lity en­gi­nee­ring and agi­lity in the con­ti­nuous de­ve­lop­ment of mi­cro­fa­bri­ca­tion sys­tems and so­lu­ti­ons.

Foun­ded in 2016, Nas­daq Stock­holm-lis­ted CEL­LINK is the world's lea­ding bio­con­ver­gence com­pany with pionee­ring tech­no­lo­gies, so­lu­ti­ons and ser­vices for me­di­cine and bio­logy. With a fo­cus on the ap­pli­ca­tion areas of bio­prin­ting, multi-omics, cell line de­ve­lop­ment and dia­gnostics, the com­pany de­ve­lops and mar­kets in­no­va­tive tech­no­lo­gies that enable life sci­ence re­se­ar­chers to cul­ture 3D-prin­ted cells, per­form drug scree­ning in high-th­rough­put pro­ces­ses, and also print hu­man tis­sue and or­gans for the me­di­cal, phar­maceuti­cal and cos­me­tics in­dus­tries.

With Na­no­scribe, the CEL­LINK Group be­co­mes the world's first life sci­ence com­pany with in­ter­nal re­sour­ces for ad­di­tive ma­nu­fac­tu­ring ba­sed on two-pho­ton po­ly­me­ri­sa­tion (2PP). The aim is to drive pro­duct de­ve­lop­ment th­roug­hout the group. By com­bi­ning CEL­LINK's state-of-the-art macro­struc­tu­ral bio­prin­ting tech­no­logy with Na­no­scribe's mi­cro­struc­tu­ral bio­prin­ting tech­no­logy, strong syn­er­gies are ex­pec­ted for 3D prin­ting more rea­listic tis­sue ar­chi­tec­tures, in­clu­ding vas­cu­la­ri­sa­tion and cell-sup­por­ting struc­tures. Na­no­scribe's 2PP tech­no­logy will enable pro­duct de­ve­lop­ments across all CEL­LINK Group busi­nes­ses and ex­pand the CEL­LINK Group's of­fe­ring.

Eb­ner Stolz struc­tu­red and ma­na­ged the ent­ire tran­sac­tion pro­cess with a mul­ti­di­sci­pli­nary team. In par­ti­cu­lar, the team led the ne­go­tia­ti­ons of the purchase agree­ment and all re­la­ted agree­ments un­til their com­ple­tion.

Team Eb­ner Stolz: Dr Chris­toph Ep­pin­ger and Flo­rian Sei­zer (M&A Fi­nan­cial, pro­ject coor­di­na­tion), Dr Ro­de­rich Fi­scher, Dr Jo­han­nes Jo­ep­gen and The­resa Reu­ter (M&A Le­gal), Lau­rent Meis­ter, LL.M (Le­gal IP/IT), Chris­tof Zond­ler and Anna Blank (M&A Tax, tran­sac­tion struc­tu­ring)

Press Contact

Hen­ning Mar­bur­ger
Eb­ner Stolz
Holz­markt 1
50676 Co­lo­gne
Phone  +49 221 20643-628
hen­ning.mar­bur­ger@eb­ner­stolz.de

Corporate Contact

Dr. Chris­toph Ep­pin­ger
Eb­ner Stolz
Kro­nen­straße 30
70174 Stutt­gart
Phone  +49 711 2049-1409
chris­toph.ep­pin­ger@eb­ner­stolz.de

About Ebner Stolz

Eb­ner Stolz is one of the lar­gest inde­pen­dent mid-mar­ket audi­ting and con­sul­ting firms in Ger­many and ranks among the top ten in the indu­s­try. The com­pany has deca­des of in-depth expe­ri­ence in audi­ting, tax con­sul­ting, le­gal con­sul­ting and mana­ge­ment con­sul­ting. This broad spec­trum is offe­red by 1,800 emp­loyees in the typi­cal mul­ti­di­s­ci­p­li­nary ap­proach in all ma­jor Ger­man ci­ties and busi­ness cen­ters. As a mar­ket lea­der in the SME sec­tor, the com­pany pre­do­mi­n­antly ser­ves me­dium-si­zed indu­s­trial, com­mer­cial and ser­vice com­pa­nies of all sec­tors and si­zes.

Eb­ner Stolz car­ries out cross-bor­der audi­ting and con­sul­ting enga­ge­ments toge­ther with part­ners from Ne­xia In­ter­na­tio­nal, one of the world’s ten lar­gest net­works of con­sul­ting and audi­ting firms. Th­rough Ne­xia, Eb­ner Stolz is rep­re­sen­ted in over 120 coun­tries with more than 720 of­fices